Analysts question Novartis' $4B peak sales estimates for MS pill

Novartis: Novartis is a Swiss multinational pharmaceutical company that develops and commercializes innovative medicines across multiple therapeutic areas including neuroscience. The company is advancing remibrutinib, an oral BTK inhibitor already approved as Rhapsido for chronic hives, through late-stage testing for relapsing multiple sclerosis. Recent trial data for this candidate showed meaningful but lower-than-anticipated efficacy against a standard therapy, which has drawn analyst scrutiny regarding its commercial outlook. Competition: A rival experimental MS drug from Roche achieved greater reductions in relapse rates than Novartis's candidate in its own pivotal studies. Safety Profile: Novartis's remibrutinib demonstrated a clean safety profile in MS trials, avoiding liver-related side effects that have affected other drugs in its class.